Tetrahydrozoline

For the treatment of minor ocular irritation and redness, the standard adult dosage is:

• Ophthalmic Solution (0.05%): Instill 1 to 2 drops into the affected eye(s) up to 4 times daily. Patients should be advised not to exceed this frequency to avoid the risk of rebound hyperemia (increased redness once the drug wears off).

For nasal congestion, the standard adult dosage is:

• Nasal Spray/Drops (0.1%): 2 to 3 sprays or drops in each nostril every 4 to 6 hours as needed. Do not use more frequently than every 4 hours or for longer than 3 consecutive days.

Tetrahydrozoline must be used with extreme caution in children. According to the American Academy of Pediatrics and FDA guidelines:

• Children under 6 years of age: Use is generally not recommended unless specifically directed by a pediatrician. There is a high risk of systemic toxicity if the drug is accidentally swallowed.
• Children 6 to 12 years of age: For ophthalmic use, 1 to 2 drops of the 0.05% solution may be used under adult supervision. For nasal use, the 0.05% concentration is preferred, with 2 to 3 drops/sprays in each nostril every 4 to 6 hours.
• Children over 12 years of age: May follow adult dosing guidelines.

Renal Impairment

Specific dosage adjustments for patients with kidney disease have not been established for topical Tetrahydrozoline. However, because systemic absorption is low when used correctly, standard dosing is typically used. Patients with severe renal failure should still consult their doctor before use.

Hepatic Impairment

No specific adjustments are required for patients with liver disease under normal topical usage. If systemic toxicity is suspected, the clearance of the drug may be delayed in those with significant hepatic dysfunction.

Elderly Patients

Geriatric patients may be more sensitive to the effects of sympathomimetic amines. While no specific dose reduction is mandated, elderly patients should use the lowest effective dose and monitor for increases in blood pressure or heart rate.

For Ophthalmic Use:

1. 1Wash hands thoroughly before use.
2. 2Tilt the head back and pull down the lower eyelid to create a small pocket.
3. 3Hold the dropper above the eye without touching the eye, eyelid, or any other surface to prevent contamination.
4. 4Squeeze one drop into the pocket and close the eye gently.
5. 5Apply light pressure to the inside corner of the eye (near the nose) for 1 minute to minimize systemic absorption.
6. 6If using other eye medications, wait at least 5 minutes between applications.

For Nasal Use:

1. 1Blow the nose gently before using the spray.
2. 2Keep the head upright and insert the spray tip into one nostril.
3. 3Sniff deeply while squeezing the bottle quickly and firmly.
4. 4Repeat in the other nostril.
5. 5Rinse the tip with hot water and dry with a clean tissue after each use.

Storage: Store at room temperature (15°C to 30°C / 59°F to 86°F) away from moisture and heat. Keep the bottle tightly closed.

If you miss a dose, use it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular timing. Do not double the dose to catch up.

An overdose of Tetrahydrozoline, particularly through oral ingestion, is a medical emergency. Signs of overdose include:

• Extreme drowsiness or lethargy
• Decreased body temperature (hypothermia)
• Slow heart rate (bradycardia)
• Low blood pressure (hypotension) followed by high blood pressure
• Respiratory depression (difficulty breathing)
• Coma

In the event of accidental ingestion, contact a Poison Control Center (1-800-222-1222 in the US) or seek emergency medical care immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or use the product for longer than 3 days without medical guidance.

Most patients tolerate Tetrahydrozoline well when used as directed for short periods. However, common localized reactions include:

• Transient Stinging or Burning: A brief sensation of irritation immediately following application to the eye or nasal passages. This usually resolves within seconds.
• Blurred Vision: Temporary blurring of vision may occur immediately after eye drop application due to the liquid consistency of the drops.
• Dryness of the Mucosa: Frequent nasal use can lead to a sensation of dryness or crusting inside the nose.
• Sneezing: Nasal application may trigger a brief sneezing reflex.

• Rebound Congestion (Rhinitis Medicamentosa): This is a significant concern with nasal use. If used for more than 3 consecutive days, the nasal passages may become more congested than they were initially as the drug's effect wears off, leading to a cycle of dependency.
• Rebound Hyperemia: Similar to the nasal effect, chronic use of eye drops can cause the blood vessels to become permanently dilated, making the eyes look chronically red when the drops are not used.
• Mydriasis (Pupil Dilation): In some individuals, Tetrahydrozoline can cause the pupils to enlarge slightly, which may increase sensitivity to light.

• Systemic Sympathomimetic Effects: These occur if the drug is absorbed into the bloodstream and may include palpitations (pounding heart), increased blood pressure, headache, and tremors.
• Insomnia and Nervousness: Rare reports of difficulty sleeping or feeling jittery, particularly in sensitive individuals or children.
• Allergic Contact Dermatitis: Redness or itching of the eyelids or skin around the nose.

> Warning: Stop taking Tetrahydrozoline and call your doctor immediately if you experience any of these.

• Severe Eye Pain: Sharp or throbbing pain in the eye after application could indicate an underlying condition or an adverse reaction to the drug.
• Vision Changes: Any sudden loss of vision, seeing halos around lights, or persistent blurred vision.
• Cardiac Arrhythmias: Irregular heartbeat or a sensation that the heart is skipping a beat.
• Severe Headache or Dizziness: May indicate a sudden spike in blood pressure.
• Signs of an Allergic Reaction: Hives, difficulty breathing, or swelling of the face, lips, tongue, or throat (anaphylaxis).

The most significant long-term risk of Tetrahydrozoline is the development of "conjunctivitis medicamentosa" or "rhinitis medicamentosa." This is a condition where the tissues of the eye or nose become physically dependent on the vasoconstrictor to maintain normal vessel tone. Over time, the tissue may become thickened (hypertrophic), and the redness or congestion may become permanent and resistant to treatment. Long-term use can also mask underlying medical conditions, such as chronic dry eye syndrome or allergic fungal sinusitis, which require different therapeutic approaches.

No FDA black box warnings are currently issued for Tetrahydrozoline. However, the FDA has issued multiple safety communications regarding the risk of serious harm or death if Tetrahydrozoline is ingested by children. The packaging for these products is required to be child-resistant under the Poison Prevention Packaging Act.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Tetrahydrozoline is intended for temporary relief only. It is not a cure for eye or nasal conditions. Patients should be aware that the most common cause of treatment failure is the development of rebound congestion due to overuse. Never share your eye drops or nasal sprays with others, as this can spread infection.

No FDA black box warnings for Tetrahydrozoline. However, the risk of pediatric toxicity via oral ingestion is considered a major public health concern.

• Narrow-Angle Glaucoma: Tetrahydrozoline is generally contraindicated in patients with narrow-angle glaucoma. Because the drug can cause slight pupillary dilation (mydriasis), it may trigger an acute attack of angle-closure glaucoma, which is a medical emergency characterized by a sudden increase in eye pressure.
• Cardiovascular Disease: Individuals with hypertension (high blood pressure), coronary artery disease, or arrhythmias should use Tetrahydrozoline with caution. Sympathomimetic amines can stimulate the heart and constrict systemic blood vessels, potentially worsening these conditions.
• Diabetes Mellitus: Use caution as alpha-adrenergic agonists can theoretically interfere with blood glucose control, although this is rare with topical use.
• Thyroid Disease: Patients with hyperthyroidism (overactive thyroid) may be more sensitive to the effects of Tetrahydrozoline and may experience increased heart rate or tremors.
• Prostatic Hyperplasia: Men with an enlarged prostate may experience increased difficulty urinating if significant systemic absorption occurs, as alpha-agonists can increase the tone of the urinary sphincter.

For standard OTC use, specific lab tests are not required. However, if a patient is using the drug under medical supervision for an extended period, the following may be monitored:

• Intraocular Pressure (IOP): To ensure the drug is not contributing to glaucoma risks.
• Blood Pressure: Especially in patients with pre-existing hypertension.
• Visual Acuity: Regular eye exams are recommended if ocular symptoms persist.

Tetrahydrozoline may cause temporary blurred vision or light sensitivity (due to pupil dilation). Patients should wait until their vision is clear before driving or operating heavy machinery. If systemic absorption causes dizziness or drowsiness, these activities should be avoided entirely.

There is no direct chemical interaction between alcohol and topical Tetrahydrozoline. However, alcohol can cause vasodilation (widening of blood vessels), which may counteract the effects of the drug and worsen eye redness or nasal congestion. Furthermore, if systemic toxicity occurs, alcohol may exacerbate CNS depression.

If you have used Tetrahydrozoline for longer than the recommended 3 days, do not stop abruptly if you experience severe rebound congestion. Instead, consult a doctor. They may recommend a tapering schedule or the use of a topical corticosteroid to help reduce the inflammation caused by the withdrawal of the vasoconstrictor.

> Important: Discuss all your medical conditions with your healthcare provider before starting Tetrahydrozoline, especially if you have a history of heart problems or glaucoma.

• Monoamine Oxidase Inhibitors (MAOIs): Drugs such as phenelzine, selegiline, or tranylcypromine should not be used within 14 days of Tetrahydrozoline. MAOIs inhibit the breakdown of sympathomimetic amines. Using them together can lead to a severe, potentially fatal hypertensive crisis (dangerously high blood pressure).

• Tricyclic Antidepressants (TCAs): Medications like amitriptyline or nortriptyline can potentiate the pressor (blood pressure-raising) response of Tetrahydrozoline. This can increase the risk of cardiovascular side effects like tachycardia (fast heart rate).
• Maprotiline: Similar to TCAs, this medication can increase the effects of sympathomimetics on the heart and blood vessels.

• Beta-Blockers: Drugs like propranolol or metoprolol may have their efficacy slightly reduced if significant systemic absorption of Tetrahydrozoline occurs. Additionally, the combination can sometimes lead to an "unopposed alpha-effect," resulting in high blood pressure.
• Other Decongestants: Using Tetrahydrozoline with other oral decongestants (like pseudoephedrine) increases the risk of systemic side effects such as jitteriness, insomnia, and palpitations.
• Ergot Alkaloids: Medications used for migraines (like ergotamine) also cause vasoconstriction. Combining them with Tetrahydrozoline may lead to excessive narrowing of blood vessels.

• Caffeine: High intake of caffeine (coffee, tea, energy drinks) while using Tetrahydrozoline can increase the risk of sympathomimetic side effects like tremors, rapid heartbeat, and anxiety.
• Alcohol: As mentioned previously, alcohol can cause facial flushing and ocular redness, which may make the drug appear less effective.

• St. John’s Wort: May have mild MAOI-like activity and should be used cautiously.
• Ephedra (Ma Huang): Contains natural sympathomimetics and should never be combined with Tetrahydrozoline due to the risk of severe cardiovascular events.
• Bitter Orange: Contains synephrine, which acts similarly to Tetrahydrozoline and can compound the risk of high blood pressure.

Tetrahydrozoline is not known to significantly interfere with common blood or urine laboratory tests. However, its effect on pupil size may interfere with certain ophthalmic diagnostic tests (such as retinal photography or glaucoma screening) if used immediately before an eye exam.

Mechanism of Interaction Summary:

Most interactions with Tetrahydrozoline are pharmacodynamic, meaning the drugs have additive or opposing effects on the same physiological systems (the sympathetic nervous system). The primary concern is the additive effect on blood pressure and heart rate.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those applied to the skin or eyes.

Tetrahydrozoline must NEVER be used in the following circumstances:

• Hypersensitivity: Any known allergy to Tetrahydrozoline or any of the inactive ingredients in the formulation (such as benzalkonium chloride, a common preservative).
• Narrow-Angle Glaucoma: As an alpha-agonist, Tetrahydrozoline can cause the iris to pull back, potentially blocking the drainage angle of the eye and causing a rapid, dangerous rise in intraocular pressure.
• Oral Ingestion: Tetrahydrozoline is for topical use only. Ingestion can lead to severe CNS depression and cardiovascular collapse, particularly in children.

Healthcare providers must weigh the risks and benefits in patients with:

• Severe Cardiovascular Disease: Including unstable angina or recent myocardial infarction (heart attack).
• Uncontrolled Hypertension: The potential for systemic absorption could push blood pressure into a dangerous range.
• Advanced Arteriosclerosis: Hardening of the arteries can make the cardiovascular system less able to handle the effects of sympathomimetic drugs.
• Rhinitis Sicca: A condition characterized by chronic dry, inflamed nasal passages, which may be worsened by the drying effect of Tetrahydrozoline.

Patients who have had allergic reactions to other imidazoline derivatives (such as oxymetazoline, naphazoline, or xylometazoline) are at a higher risk of being allergic to Tetrahydrozoline. If you have reacted to other "redness relief" eye drops or long-acting nasal sprays, consult an allergist before using Tetrahydrozoline.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing or recommending Tetrahydrozoline to ensure it is safe for your specific health profile.

FDA Pregnancy Category C: Animal reproduction studies have not been conducted with Tetrahydrozoline. It is also not known whether Tetrahydrozoline can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

• First Trimester: Vasoconstrictors should be used with extreme caution. There is a theoretical risk that systemic absorption could affect uterine blood flow.
• Second and Third Trimesters: Use should be limited to short durations and only if the potential benefit justifies the potential risk to the fetus. Most obstetricians recommend saline-based eye drops or nasal sprays as a first-line alternative.

It is not known whether Tetrahydrozoline is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from sympathomimetic amines, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Given its short-term use, most providers suggest avoiding it while breastfeeding to prevent any risk of the infant experiencing tachycardia or irritability.

Tetrahydrozoline is particularly dangerous to the pediatric population.

• Toxicity Risk: The imidazoline class of drugs can cause profound CNS depression in children. Even a small amount of eye drops (1-2 mL) ingested orally can cause a child to fall into a coma, experience dangerously slow heart rates, and require intubation.
• Approved Age: While some OTC labels allow use in children over 6, many clinicians advise against its use in children under 12 due to the risk of misuse and systemic absorption.

In patients over 65, the risk of systemic side effects is increased.

• Cardiovascular Sensitivity: Elderly patients are more likely to have underlying heart disease or hypertension, making the systemic effects of alpha-agonists more dangerous.
• Dry Eye Syndrome: This condition is more prevalent in the elderly. Using Tetrahydrozoline can worsen dry eyes by causing further irritation and masking the need for artificial tears or prescription treatments.

While systemic absorption is minimal, the kidneys are the primary route of elimination for any absorbed drug. Patients with end-stage renal disease (ESRD) should be monitored for signs of systemic toxicity, although no specific dose adjustments are provided by manufacturers.

There are no specific guidelines for Tetrahydrozoline use in patients with liver impairment. However, as with renal impairment, clinicians should be alert for signs of prolonged drug effect if systemic absorption occurs in patients with severe cirrhosis (Child-Pugh Class C).

> Important: Special populations require individualized medical assessment. Always consult a pediatrician before giving this medication to a child and inform your doctor if you are pregnant or nursing.

Tetrahydrozoline is a sympathomimetic agent that primarily targets alpha-adrenergic receptors. It is a derivative of imidazoline. Its primary molecular action is as an agonist at alpha-1 adrenoceptors located on the vascular smooth muscle cells of the conjunctival and nasal mucosal blood vessels.

Upon binding to these receptors, Tetrahydrozoline activates the Gq protein-coupled signaling pathway, leading to the activation of phospholipase C. This results in an increase in intracellular calcium levels, which triggers the contraction of the smooth muscle fibers. This contraction narrows the lumen of the blood vessels (vasoconstriction), thereby reducing the physical diameter of the vessels and decreasing the amount of fluid that can leak into surrounding tissues. This effectively reduces redness and edema.

• Onset of Action: Very rapid, usually within 60 to 300 seconds (1-5 minutes).
• Peak Effect: Occurs within 15 to 30 minutes of topical application.
• Duration of Action: Typically lasts for 4 to 8 hours.
• Tolerance: Tachyphylaxis (a rapid decrease in response to the drug) can occur with frequent use. This is why the drug becomes less effective over time, leading patients to use more of it, which eventually causes rebound congestion.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Topical); High (Oral/Ingested) |

| Protein Binding | Not characterized in humans |

| Half-life | ~2 to 4 hours (systemic) |

| Tmax | <1 hour (systemic absorption) |

| Metabolism | Hepatic (minimal if used topically) |

| Excretion | Renal |

• Molecular Formula: C13H16N2 (as free base); C13H17ClN2 (as Hydrochloride)
• Molecular Weight: 236.74 g/mol (Hydrochloride)
• Solubility: Freely soluble in water and in alcohol; practically insoluble in ether.
• Structure: It consists of a tetrahydro-1-naphthyl group attached to an imidazoline ring. This structure is characteristic of the imidazoline decongestant class, which also includes oxymetazoline and naphazoline.

Tetrahydrozoline is classified as an Alpha-Adrenergic Agonist and a Topical Decongestant. Within the EphMRA anatomical classification, it is categorized under S01GA02 (Ophthalmologicals, Decongestants). It is related to other sympathomimetics but is distinct in its preference for topical application over systemic (oral) use due to its potent CNS effects if absorbed systemically.